Slide 1: Full Year Results FY 2025
Full Year Results FY 2025 21 August 2025
Slide 2: Important Information: Forward-looking statements
Important Information: Forward-looking statements This presentation may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Healius Limited. Readers are cautioned not to pla
Slide 3: Group Overview
Group Overview Paul Anderson Chief Executive Officer & Managing Director 3
Slide 4: Group Results
Group Results Simpler business model post Lumus sale, debt repaid and Pathology strategy execution well underway Revenue Pathology Revenue Financial Performance $1.34b $1.30b Revenue • Group revenue growth of 5.7% $1.27b in pcp (up 5.7%) $1.23b in pcp (up 6.0%) • Pathology revenue (ex Agilex) growth
Slide 5: Pathology (excluding Agilex Biolabs & Corporate)
Pathology (excluding Agilex Biolabs & Corporate) Strong improvement in revenue growth, revenue mix changing, customer focus progress, labour cost reduction underway Financial • Revenue $1,302.1m growth of 6.0% on pcp • Labour costs running at almost half of revenue – actions to reduce in place • EBI
Slide 6: Pathology Strategy
Pathology Strategy Execution of strategy well underway with a defined plan and progress post Investor Day Focused on providing better services for our patients and referrers to improve the volume and quality of the revenue we generate and to become more efficient in our processes Customer Laboratory
Slide 7: Investor Day March 2025 – Plan Update
Investor Day March 2025 – Plan Update Delivering on the T27 strategic plan T27 High EBIT Margin % single digit % 2.4%* FY25 FY26 FY27 Customer service Growth in core Better network & Enhanced 1 2 collections productivity 3 business customer experience Laboratory Efficient & quality Logistics Reduced
Slide 8: T27 Scorecard – Performance Update
T27 Scorecard – Performance Update ✓ Delivery complete ▸ Partially delivered > On track Our goal is to deliver high single digit EBIT margin in FY27 ✓• Medway Collections Portal: rolled out to all ACCs (since 28 Jul) ▸• Collection labour planning: benefit from 1Q26 onwards Customer Service ✓• Appoin
Slide 9: Agilex Biolabs
Agilex Biolabs FY25 year impacted by global uncertainty / 1Q26 improvement Financial • Revenue $38.2m vs $39.5m in FY24 • EBITDA of $6.4m vs $8.9m in FY24 • EBIT of $2.7m vs $5.1m in FY24 Operational • FY25 was a difficult year due to a range of geopolitical issues, including volatility on health po
Slide 10: Summary Financials
Summary Financials Steve Humphries Chief Financial Officer 10
Slide 11: Group Results
Group Results Revenue growth continues with cost focus FY25 FY24 Top line revenue growth / strategy to reduce costs $m $m Chg % • Group revenue growth of 5.7% to $1,344.5m Revenue (Underlying) 1,344.5 1,272.2 5.7% • 2H25 volumes adversely impacted by Tropical Cyclone Alfred with EBITDA (Underlying)
Slide 12: Pathology
Pathology Improving revenue mix FY25 FY24 Revenue growth 6.0% - improvements in revenue mix $m $m Chg % Revenue 1,302.1 1,228.6 6.0% • Revenue growth underpinned by volume (3.3%) and average fee (1.9%) through improved mix of Specialists and B2B revenues EBITDA 244.2 251.7 (3.0%) - Strong growth con
Slide 13: Agilex Biolabs
Agilex Biolabs Global uncertainty easing FY25 FY24 Global market uncertainty impacted revenue $m $m Chg % • EBIT margin of 7.1% reflects the slight decline in revenue, and Revenue 38.2 39.5 (3.3%) change in mix as business pivoted away from small molecule to large molecule work in response to change
Slide 14: Corporate
Corporate Cost-out program is well advanced FY25 FY24 • Represents centrally managed support services net of allocations $m $m Chg % to operating businesses Revenue 4.2 4.2 0.0% • EBITDA is in line with FY24 due to tight cost control • Well progressed with separation and cost out program for simpler
Slide 15: Capital Management
Capital Management Including Lumus cash flows Net debt bridge ($m) Capex • Maintenance capex $16.0m, primarily for equipment replacement and site refurbishments for ACCs (299.9) • Growth capex $16.0m mainly comprises new ACCs 57.2 and investment in IT and Digital program • Expect FY26 maintenance ca
Slide 16: FY26 Outlook
FY26 Outlook Revenue mix and labour costs focus for FY26 • Revenue growth expected to be consistent with 2H25 - Volumes up 2.4% for the year to date (compared to 1.6% for 2H25) - B12 / Urine changes in place ▪ Impact yet to be fully understood across the Pathology market • Cost growth minimised by e
Slide 17: Q&A
Q&A
Slide 18: Appendix
Appendix 18
Slide 19: Underlying to Reported Reconciliation
Underlying to Reported Reconciliation FY25 FY24 FY25 FY24 $m $m $m $m Underlying EBIT 17.1 23.5 Underlying EBIT 17.1 23.5 Digital transformation costs (19.6) (25.8) Interest (65.1) (60.4) Transaction and takeover bid costs (1.6) (7.5) Notional interest recharged to Lumus Imaging 12.6 14.3 Restructur
Slide 20: Capital Management
Capital Management Group cash flows with net Lumus cashflows presented separately Net debt bridge ($m) (299.9) 57.2 (0.2) 795.2 (32.0) (9.4) (29.9) 239.3 (217.1) (360.7) (28.1) Opening Underlying Non- Working Capex Lease Interest Net Dividend Lumus Closing net debt EBITDA underlying capital & and ot
Slide 21: Thank you
Thank you